Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients

G. Montes Diaz, J. Fraussen, B. Van Wijmeersch, R. Hupperts, V. Somers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

39 Citations (Web of Science)

Abstract

The effects of dimethyl fumarate (DMF) on the immune system in multiple sclerosis (MS) are not completely elucidated. In this study, an extensive immunophenotypic analysis of innate and adaptive immune cells of DMF-treated MS patients was performed. Peripheral blood immune cell phenotypes were determined using flow cytometry in a follow-up study of 12 MS patients before, after 3 and 12 months of DMF treatment and a cross-sectional study of 25 untreated and 64 DMF-treated MS patients. Direct effects of DMF on B cells were analyzed in vitro. After 12 months of DMF treatment, percentages of monocytes, natural killer cells, naive T and B cells and transitional B cells increased. Percentages of (effector) memory T cells, (non) class-switched memory B cells and double negative B cells decreased together with CD4(+) T cells expressing interferon-gamma (IFN-gamma), granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-17 (IL-17). DMF treatment was fully effective as of 6 months and directly induced apoptosis and decreased expression of costimulatory CD40, antigen presentation molecule MHCII and B cell activating factor receptor (BAFFR) on B cells. DMF induced a persistent change of the immune system of MS patients, directly induced apoptosis and reduced expression of functional markers on B cells.
Original languageEnglish
Article number8194
Number of pages13
JournalScientific Reports
Volume8
DOIs
Publication statusPublished - 29 May 2018

Keywords

  • MEMORY T-CELLS
  • PLACEBO-CONTROLLED PHASE-3
  • NATURAL-KILLER-CELLS
  • FACTOR-KAPPA-B
  • NUCLEAR-FACTOR
  • ACID ESTERS
  • ORAL BG-12
  • EXPRESSION
  • AUTOIMMUNE
  • RESPONSES

Cite this